Randomised controlled trial of Tumour necrosis factor inhibitors Against Combination Intensive Therapy with conventional disease-modifying antirheumatic drugs in established rheumatoid arthritis: The TACIT trial and associated systematic reviews

Health Technology Assessment

Volumn 18, Issue 66, 2014, Pages 1-164

  Scott, David L ^a   Ibrahim, Fowzia ^a   Farewell, Vern ^b   O’Keeffe, Aidan G ^b   Ma, Margaret ^a   Walker, David ^c   Heslin, Margaret ^d   Patel, Anita ^d   Kingsley, Gabrielle ^a  

^a KING'S COLLEGE LONDON   (United Kingdom)

^b UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^c FREEMAN HOSPITAL   (United Kingdom)

^d KING'S COLLEGE LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ADALIMUMAB; ALANINE AMINOTRANSFERASE; CYCLOSPORIN A; DISEASE MODIFYING ANTIRHEUMATIC DRUG; ETANERCEPT; GLUCOCORTICOID; GOLD; HYDROXYCHLOROQUINE; INFLIXIMAB; LEFLUNOMIDE; METHOTREXATE; PREDNISOLONE; SALAZOSULFAPYRIDINE; TUMOR NECROSIS FACTOR INHIBITOR; ANTIRHEUMATIC AGENT; TUMOR NECROSIS FACTOR ALPHA;

ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; CHEST INFECTION; COMMON COLD; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; COST UTILITY ANALYSIS; COUGHING; DAS28; DIARRHEA; DISEASE ACTIVITY; DISEASE DURATION; DISEASE EXACERBATION; DIZZINESS; DRUG COST; DRUG EFFICACY; DRUG RESPONSE; DRUG SUBSTITUTION; DRUG TOXICITY; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; DYSPNEA; EUROPEAN QUALITY OF LIFE 5 DIMENSIONS; FATIGUE; FEMALE; HEADACHE; HEATH ASSESSMENT QUESTIONNAIRE; HUMAN; HYPERTENSION; INFLUENZA; INJECTION SITE REACTION; KNEE PAIN; LEUKOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; MORTALITY; MOUTH PAIN; MOUTH ULCER; MULTICENTER STUDY; NAMED INVENTORIES, QUESTIONNAIRES AND RATING SCALES; NAUSEA; OUTCOME ASSESSMENT; PRURITUS; QUALITY ADJUSTED LIFE YEAR; RANDOMIZED CONTROLLED TRIAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REMISSION; RHEUMATOID ARTHRITIS; SHORT FORM 36; SHOULDER PAIN; SIDE EFFECT; SORE THROAT; SYSTEMATIC REVIEW; THORAX PAIN; THRUSH; TREATMENT DURATION; UPPER RESPIRATORY TRACT INFECTION; URINARY TRACT INFECTION; VAGINAL THRUSH; VOMITING; AGED; ANTAGONISTS AND INHIBITORS; ARTHRITIS, RHEUMATOID; CLINICAL TRIAL; COST BENEFIT ANALYSIS; COST OF ILLNESS; DRUG COMBINATION; ECONOMICS; MIDDLE AGED; QUALITY OF LIFE; SEVERITY OF ILLNESS INDEX; SOCIAL WORK; SOCIOECONOMICS; UNITED KINGDOM;

AGED; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; COST OF ILLNESS; COST-BENEFIT ANALYSIS; DRUG THERAPY, COMBINATION; ENGLAND; FEMALE; HUMANS; MALE; METHOTREXATE; MIDDLE AGED; QUALITY OF LIFE; QUALITY-ADJUSTED LIFE YEARS; SEVERITY OF ILLNESS INDEX; SOCIAL WORK; SOCIOECONOMIC FACTORS; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84912043640     PISSN: 13665278     EISSN: 20464924     Source Type: Journal    
DOI: 10.3310/hta18660     Document Type: Article

References (303)

1. Scott DL, Wolfe F, Huizinga TW. Rheumatoid arthritis. Lancet 2010; 376: 1094-108. http://dx. doi. org/10. 1016/S0140-6736(10)60826-4.
2. Klarenbeek NB, Kerstens PJ, Huizinga TW, Dijkmans BA, Allaart CF. Recent advances in the management of rheumatoid arthritis. BMJ 2010; 341: c6942. http://dx. doi. org/10. 1136/bmj. c6942.
3. McInnes IB, Schett G. The pathogenesis of rheumatoid arthritis. N Engl J Med 2011; 365: 2205-19. http://dx. doi. org/10. 1056/NEJMra1004965.
4. Ropes MW, Bennett GA, Cobb S, Jacox R, Jessar RA. 1958 revision of diagnostic criteria for rheumatoid arthritis. Arthritis Rheum 1959; 2: 16-20. http://dx. doi. org/10. 1002/1529-0131 (195902)2: 1<16:: AID-ART1780020104>3. 0. CO; 2-9.
5. Arnett FC, Edworthy SM, Bloch DA, McShane DJ, Fries JF, Cooper NS, et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 1988; 31: 315-24. http://dx. doi. org/10. 1002/art. 1780310302.
6. Aletaha D, Neogi T, Silman A, Funovits J, Felson D, Bingham CO III, et al. The 2010 American College of Rheumatology/European League against Rheumatism classification criteria for rheumatoid arthritis. Ann Rheum Dis 2010; 69: 1580-8. http://dx. doi. org/10. 1136/ard. 2010. 138461.
7. Scott DL, Steer S. The course of established rheumatoid arthritis. Best Pract Res Clin Rheumatol 2007; 21: 943-67. http://dx. doi. org/10. 1016/j. berh. 2007. 05. 006.
8. Young A, Koduri G. Extra-articular manifestations and complications of rheumatoid arthritis. Best Pract Res Clin Rheumatol 2007; 21: 907-27. http://dx. doi. org/10. 1016/j. berh. 2007. 05. 007.
9. Sokka T, Abelson B, Pincus T. Mortality in rheumatoid arthritis: 2008 update. Clin Exp Rheumatol 2008; 26(Suppl. 51): S35-61.
10. Allaire S, Wolfe F, Niu J, LaValley MP, Zhang B, Reisine S. Current risk factors for work disability associated with rheumatoid arthritis: recent data from a US national cohort. Arthritis Rheum 2009; 61: 321-8. http://dx. doi. org/10. 1002/art. 24281.
11. Smolen JS, van der Heijde DM, Aletaha D, Xu S, Han J, Baker D, et al. Progression of radiographic joint damage in rheumatoid arthritis: independence of erosions and joint space narrowing. Ann Rheum Dis 2009; 68: 1535-40. http://dx. doi. org/10. 1136/ard. 2008. 094128.
12. Michaud K, Wolfe F. Comorbidities in rheumatoid arthritis. Best Pract Res Clin Rheumatol 2007; 21: 885-906. http://dx. doi. org/10. 1016/j. berh. 2007. 06. 002.
13. Dougados M, Aletaha D, van Riel P. Disease activity measures for rheumatoid arthritis. Clin Exp Rheumatol 2007; 25(Suppl. 46): S22-9.
14. Nishimura K, Sugiyama D, Kogata Y, Tsuji G, Nakazawa T, Kawano S, et al. Meta-analysis: diagnostic accuracy of anti-cyclic citrullinated peptide antibody and rheumatoid factor for rheumatoid arthritis. Ann Intern Med 2007; 146: 797-808. http://dx. doi. org/10. 7326/0003-4819-146-11-200706050-00008.
15. van der Linden MP, van der Woude D, Ioan-Facsinay A, Levarht EW, Stoeken-Rijsbergen G, Huizinga TW, et al. Value of anti-modified citrullinated vimentin and third-generation anti-cyclic citrullinated peptide compared with second-generation anti-cyclic citrullinated peptide and rheumatoid factor in predicting disease outcome in undifferentiated arthritis and rheumatoid arthritis. Arthritis Rheum 2009; 60: 2232-41. http://dx. doi. org/10. 1002/art. 24716.
16. Whiting PF, Smidt N, Sterne JA, Harbord R, Burton A, Burke M, et al. Systematic review: accuracy of anti-citrullinated peptide antibodies for diagnosing rheumatoid arthritis. Ann Intern Med 2010; 152: 456-64. http://dx. doi. org/10. 7326/0003-4819-152-7-201004060-00010.
17. Yazici Y, Sokka T, Pincus T. Radiographic measures to assess patients with rheumatoid arthritis: advantages and limitations. Rheum Dis Clin North Am 2009; 35: 723-9. http://dx. doi. org/10. 1016/j. rdc. 2009. 10. 005.
18. Boutry N, Morel M, Flipo RM, Demondion X, Cotten A. Early rheumatoid arthritis: a review of MRI and sonographic findings. Am J Roentgenol 2007; 189: 1502-9. http://dx. doi. org/10. 2214/AJR. 07. 2548.
19. Kubassova O, Boesen M, Peloschek P, Langs G, Cimmino MA, Bliddal H, et al. Quantifying disease activity and damage by imaging in rheumatoid arthritis and osteoarthritis. Ann N Y Acad Sci 2009; 1154: 207-38. http://dx. doi. org/10. 1111/j. 1749-6632. 2009. 04392. x.
20. Jacob N, Jacob CO. Genetics of rheumatoid arthritis: an impressionist perspective. Rheum Dis Clin North Am 2012; 38: 243-57. http://dx. doi. org/10. 1016/j. rdc. 2012. 05. 001.
21. Sugiyama D, Nishimura K, Tamaki K, Tsuji G, Nakazawa T, Morinobu A, et al. Impact of smoking as a risk factor for developing rheumatoid arthritis: a meta-analysis of observational studies. Ann Rheum Dis 2010; 69: 70-81. http://dx. doi. org/10. 1136/ard. 2008. 096487.
22. van Venrooij WJ, van Beers JJ, Pruijn GJ. Anti-CCP antibodies: the past, the present and the future. Nat Rev Rheumatol 2011; 7: 391-8. http://dx. doi. org/10. 1038/nrrheum. 2011. 76.
23. Pugner KM, Scott D, Holmes JW, Hieke K. The costs of rheumatoid arthritis: an international long-term view. Semin Arthritis Rheum 2000; 29: 305-20. http://dx. doi. org/10. 1016/S0049-0172(00)80017-7.
24. Bansback N, Marra CA, Finckh A, Anis A. The economics of treatment in early rheumatoid arthritis. Best Pract Res Clin Rheumatol 2009; 23: 83-92. http://dx. doi. org/10. 1016/j. berh. 2008. 11. 005.
25. Nixon RM, O'Hagan A, Oakley J, Madan J, Stevens JW, Bansback N, et al. The Rheumatoid Arthritis Drug Development Model: a case study in Bayesian clinical trial simulation. Pharm Stat 2009; 8: 371-89. http://dx. doi. org/10. 1002/pst. 368.
26. National Audit Office. Services for People with Rheumatoid Arthritis. London: The Stationery Office; 2009.
27. van Riel PL, Fransen J. Established rheumatoid arthritis: clinical assessments. Best Pract Res Clin Rheumatol 2007; 21: 807-25. http://dx. doi. org/10. 1016/j. berh. 2007. 06. 001.
28. Wells GA. Patient-driven outcomes in rheumatoid arthritis. J Rheumatol Suppl 2009; 82: 33-8. http://dx. doi. org/10. 3899/jrheum. 090129.
29. Sokka T, Rannio T, Khan NA. Disease activity assessment and patient-reported outcomes in patients with early rheumatoid arthritis. Rheum Dis Clin North Am 2012; 38: 299-310. http://dx. doi. org/10. 1016/j. rdc. 2012. 04. 005.
30. Bruce B, Fries JF. The Health Assessment Questionnaire (HAQ). Clin Exp Rheumatol 2005; 23(Suppl. 39): S14-18.
31. Wolfe F. Fatigue assessments in rheumatoid arthritis: comparative performance of visual analog scales and longer fatigue questionnaires in 7760 patients. J Rheumatol 2004; 31: 1896-902.
32. Gettings L. Psychological well-being in rheumatoid arthritis: a review of the literature. Musculoskeletal Care 2010; 8: 99-106. http://dx. doi. org/10. 1002/msc. 171.
33. Fransen J, van Riel PL. The Disease Activity Score and the EULAR response criteria. Rheum Dis Clin North Am 2009; 35: 745-57. http://dx. doi. org/10. 1016/j. rdc. 2009. 10. 001.
34. Aletaha D, Smolen JS. The Simplified Disease Activity Index and Clinical Disease Activity Index to monitor patients in standard clinical care. Rheum Dis Clin North Am 2009; 35: 759-72. http://dx. doi. org/10. 1016/j. rdc. 2009. 10. 006.
35. Felson DT, Anderson JJ, Boers M, Bombardier C, Furst D, Goldsmith C, et al. American College of Rheumatology preliminary definition of improvement in rheumatoid arthritis. Arthritis Rheum 1995; 38: 727-35. http://dx. doi. org/10. 1002/art. 1780380602.
36. Thabet MM, Huizinga TW, van der Heijde DM, van der Helm-van Mil AH. The prognostic value of baseline erosions in undifferentiated arthritis. Arthritis Res Ther 2009; 11: R155. http://dx. doi. org/10. 1186/ar2832.
37. Scott DL. Radiological progression in established rheumatoid arthritis. J Rheumatol Suppl 2004; 69: 55-65.
38. Baillet A, Gaujoux-Viala C, Mouterde G, Pham T, Tebib J, Saraux A, et al. Comparison of the efficacy of sonography, magnetic resonance imaging and conventional radiography for the detection of bone erosions in rheumatoid arthritis patients: a systematic review and meta-analysis. Rheumatology 2011; 50: 1137-47. http://dx. doi. org/10. 1093/rheumatology/keq437.
39. Keystone EC, Smolen J, van Riel P. Developing an effective treatment algorithm for rheumatoid arthritis. Rheumatology 2012; 51(Suppl. 5): 48-54. http://dx. doi. org/10. 1093/rheumatology/kes122.
40. Felson D. Defining remission in rheumatoid arthritis. Ann Rheum Dis 2012; 71(Suppl. 2): 86-8. http://dx. doi. org/10. 1136/annrheumdis-2011-200618.
41. Ma MH, Scott IC, Kingsley GH, Scott DL. Remission in early rheumatoid arthritis. J Rheumatol 2010; 37: 1444-53. http://dx. doi. org/10. 3899/jrheum. 091131.
42. Thiele K, Huscher D, Bischoff S, Späthling-Mestekemper S, Backhaus M, Aringer M, et al. Performance of the 2011 ACR/EULAR preliminary remission criteria compared with DAS28 remission in unselected patients with rheumatoid arthritis. Ann Rheum Dis 2013; 72: 1194-9. http://dx. doi. org/10. 1136/annrheumdis-2012-201821.
43. Bakker MF, Jacobs JW, Verstappen SM, Bijlsma JW. Tight control in the treatment of rheumatoid arthritis: efficacy and feasibility. Ann Rheum Dis 2007; 66(Suppl. 3): iii56-60. http://dx. doi. org/10. 1136/ard. 2007. 078360.
44. Scott DL. Biologics-based therapy for the treatment of rheumatoid arthritis. Clin Pharmacol Ther 2012; 91: 30-43. http://dx. doi. org/10. 1038/clpt. 2011. 278.
45. Boers M, van Tuyl L, van den Broek M, Kostense PJ, Allaart CF. Meta-analysis suggests that intensive non-biological combination therapy with step-down prednisolone (COBRA strategy) may also 'disconnect' disease activity and damage in rheumatoid arthritis. Ann Rheum Dis 2013; 72: 406-9. http://dx. doi. org/10. 1136/annrheumdis-2012-202333.
46. Westhovens R, Verschueren P. Rheumatoid arthritis: defining remission in patients with RA in clinical practice. Nat Rev Rheumatol 2012; 8: 445-7. http://dx. doi. org/10. 1038/nrrheum. 2012. 111.
47. Jurgens MS, Jacobs JW, Bijlsma JW. The use of conventional disease-modifying anti-rheumatic drugs in established RA. Best Pract Res Clin Rheumatol 2011; 25: 523-33. http://dx. doi. org/10. 1016/j. berh. 2011. 10. 006.
48. Strand V, Scott DL, Emery P, Kalden JR, Smolen JS, Cannon GW, et al. Leflunomide Rheumatoid Arthritis Investigators Groups. Physical function and health related quality of life: analysis of 2-year data from randomized, controlled studies of leflunomide, sulfasalazine, or methotrexate in patients with active rheumatoid arthritis. J Rheumatol 2005; 32: 590-601.
49. Finckh A, Liang MH, van Herckenrode CM, de Pablo P. Long-term impact of early treatment on radiographic progression in rheumatoid arthritis: a meta-analysis. Arthritis Rheum 2006; 55: 864-72. http://dx. doi. org/10. 1002/art. 22353.
50. Visser K, Katchamart W, Loza E, Martinez-Lopez JA, Salliot C, Trudeau J, et al. Multinational evidence-based recommendations for the use of methotrexate in rheumatic disorders with a focus on rheumatoid arthritis: integrating systematic literature research and expert opinion of a broad international panel of rheumatologists in the 3E Initiative. Ann Rheum Dis 2009; 68: 1086-93. http://dx. doi. org/10. 1136/ard. 2008. 094474.
51. Jobanputra P, Wilson J, Douglas K, Burls A. A survey of British rheumatologists' DMARD preferences for rheumatoid arthritis. Rheumatology 2004; 43: 206-10. http://dx. doi. org/10. 1093/rheumatology/keh003.
52. Gaujoux-Viala C, Smolen JS, Landewé R, Dougados M, Kvien TK, Mola EM, et al. Current evidence for the management of rheumatoid arthritis with synthetic disease-modifying antirheumatic drugs: a systematic literature review informing the EULAR recommendations for the management of rheumatoid arthritis. Ann Rheum Dis 2010; 69: 1004-9. http://dx. doi. org/10. 1136/ard. 2009. 127225.
53. Mouterde G, Baillet A, Gaujoux-Viala C, Cantagrel A, Wendling D, Le Loët X, et al. Optimizing methotrexate therapy in rheumatoid arthritis: a systematic literature review. Joint Bone Spine 2011; 78: 587-92. http://dx. doi. org/10. 1016/j. jbspin. 2011. 01. 010.
54. Suarez-Almazor ME, Belseck E, Shea B, Wells G, Tugwell P. Sulfasalazine for rheumatoid arthritis. Cochrane Database Syst Rev 2000; 2: CD000958.
55. Osiri M, Shea B, Robinson V, Suarez-Almazor M, Strand V, Tugwell P, et al. Leflunomide for the treatment of rheumatoid arthritis: a systematic review and metaanalysis. J Rheumatol 2003; 30: 1182-90.
56. Suarez-Almazor ME, Belseck E, Shea B, Homik J, Wells G, Tugwell P, et al. Antimalarials for treating rheumatoid arthritis. Cochrane Database Syst Rev 2000; 4: CD000959.
57. Clark P, Tugwell P, Bennet K, Bombardier C, Shea B, Wells G, et al. Injectable gold for rheumatoid arthritis. Cochrane Database Syst Rev 2000; 2: CD000520.
58. Suarez-Almazor ME, Spooner C, Belseck E. Azathioprine for treating rheumatoid arthritis. Cochrane Database Syst Rev 2000; 4: CD001461.
59. Gotzsche PC, Johansen HK. Short-term low-dose corticosteroids vs placebo and nonsteroidal antiinflammatory drugs in rheumatoid arthritis. Cochrane Database Syst Rev 2004; 3: CD000189.
60. Kirwan JR, Bijlsma JW, Boers M, Shea BJ. Effects of glucocorticoids on radiological progression in rheumatoid arthritis. Cochrane Database Syst Rev 2007; 1: CD006356.
61. Gorter SL, Bijlsma JW, Cutolo M, Gomez-Reino J, Kouloumas M, Smolen JS, et al. Current evidence for the management of rheumatoid arthritis with glucocorticoids: a systematic literature review informing the EULAR recommendations for the management of rheumatoid arthritis. Ann Rheum Dis 2010; 69: 1010-14. http://dx. doi. org/10. 1136/ard. 2009. 127332.
62. McCarty DJ. Treating intractable rheumatoid arthritis. N Engl J Med 1981; 305: 1009-11. http://dx. doi. org/10. 1056/NEJM198110223051710.
63. Porter DR, Capell HA, Hunter J. Combination therapy in rheumatoid arthritis-no benefit of addition of hydroxychloroquine to patients with a suboptimal response to intramuscular gold therapy. J Rheumatol 1993; 20: 645-9.
64. Willkens RF, Urowitz MB, Stablein DM, McKendry RJ Jr, Berger RG, Box JH, et al. Comparison of azathioprine, methotrexate, and the combination of both in the treatment of rheumatoid arthritis. A controlled clinical trial. Arthritis Rheum 1992; 35: 849-56. http://dx. doi. org/10. 1002/art. 1780350802.
65. Felson DT, Anderson JJ, Meenan RF. The efficacy and toxicity of combination therapy in rheumatoid arthritis. A meta-analysis. Arthritis Rheum 1994; 37: 1487-91. http://dx. doi. org/10. 1002/art. 1780371012.
66. Tugwell P, Pincus T, Yocum D, Stein M, Gluck O, Kraag G, et al. Combination therapy with cyclosporine and methotrexate in severe rheumatoid arthritis. The Methotrexate-Cyclosporine Combination Study Group. N Engl J Med 1995; 333: 137-41. http://dx. doi. org/10. 1056/NEJM199507203330301.
67. O'Dell JR, Haire CE, Erikson N, Drymalski W, Palmer W, Eckhoff PJ, et al. Treatment of rheumatoid arthritis with methotrexate alone, sulfasalazine and hydroxychloroquine, or a combination of all three medications. N Engl J Med 1996; 334: 1287-91. http://dx. doi. org/10. 1056/NEJM199605163342002.
68. Boers M, Verhoeven AC, Markusse HM, van de Laar MA, Westhovens R, van Denderen JC, et al. Randomised comparison of combined step-down prednisolone, methotrexate and suphasalazine with sulphasalazine alone in early rheumatoid arthritis. Lancet 1997; 350: 309-18. http://dx. doi. org/10. 1016/S0140-6736(97)01300-7.
69. van Eijk IC, Nielen MM, van der Horst-Bruinsma I, Tijhuis GJ, Boers M, Dijkmans BA, et al. Aggressive therapy in patients with early arthritis results in similar outcome compared with conventional care: the STREAM randomized trial. Rheumatology 2012; 51: 686-94. http://dx. doi. org/10. 1093/rheumatology/ker355.
70. Choy EH, Smith C, Dore CJ, Scott DL. A meta-analysis of the efficacy and toxicity of combining disease-modifying anti-rheumatic drugs in rheumatoid arthritis based on patient withdrawal. Rheumatology 2005; 44: 1414-21. http://dx. doi. org/10. 1093/rheumatology/kei031.
71. Kiely P, Williams R, Walsh D, Young A. Early Rheumatoid Arthritis Network. Contemporary patterns of care and disease activity outcome in early rheumatoid arthritis: the ERAN cohort. Rheumatology 2009; 48: 57-60. http://dx. doi. org/10. 1093/rheumatology/ken406.
72. Deighton C, O'Mahony R, Tosh J, Turner C, Rudolf M; Guideline Development Group. Management of rheumatoid arthritis: summary of NICE guidance. BMJ 2009; 338: b702. http://dx. doi. org/10. 1136/bmj. b702.
73. Feldmann M. Development of anti-TNF therapy for rheumatoid arthritis. Nat Rev Immunol 2002; 2: 364-71. http://dx. doi. org/10. 1038/nri802.
74. Elliott MJ, Maini RN, Feldmann M, Long-Fox A, Charles P, Katsikis P, et al. Treatment of rheumatoid arthritis with chimeric monoclonal antibodies to tumor necrosis factor alpha. Arthritis Rheum 1993; 36: 1681-90. http://dx. doi. org/10. 1002/art. 1780361206.
75. Elliott MJ, Maini RN, Feldmann M, Kalden JR, Antoni C, Smolen JS, et al. Randomised double-blind comparison of chimeric monoclonal antibody to tumour necrosis factor alpha (cA2) versus placebo in rheumatoid arthritis. Lancet 1994; 344: 1105-10. http://dx. doi. org/10. 1016/S0140-6736(94)90628-9.
76. Zintzaras E, Dahabreh IJ, Giannouli S, Voulgarelis M, Moutsopoulos HM. Infliximab and methotrexate in the treatment of rheumatoid arthritis: a systematic review and meta-analysis of dosage regimens. Clin Ther 2008; 30: 1939-55. http://dx. doi. org/10. 1016/j. clinthera. 2008. 11. 007.
77. Wiens A, Correr CJ, Pontarolo R, Venson R, Quinalha JV, Otuki MF. A systematic review and meta-analysis of the efficacy and safety of etanercept for treating rheumatoid arthritis. Scand J Immunol 2009; 70: 337-44. http://dx. doi. org/10. 1111/j. 1365-3083. 2009. 02296. x.
78. Wiens A, Correr CJ, Venson R, Otuki MF, Pontarolo R. A systematic review and meta-analysis of the efficacy and safety of adalimumab for treating rheumatoid arthritis. Rheumatol Int 2010; 30: 1063-70. http://dx. doi. org/10. 1007/s00296-009-1111-4.
79. Singh JA, Noorbaloochi S, Singh G. Golimumab for rheumatoid arthritis: a systematic review. J Rheumatol 2010; 37: 1096-104. http://dx. doi. org/10. 3899/jrheum. 091466.
80. Ruiz Garcia V, Jobanputra P, Burls A, Cabello JB, Gálvez Muñoz JG, Saiz Cuenca ES, et al. Certolizumab pegol (CDP870) for rheumatoid arthritis in adults. Cochrane Database Syst Rev 2011; 2: CD007649. http://dx. doi. org/10. 1002/14651858. CD007649. pub2.
81. National Institute for Health and Care Excellence. Adalimumab, Etanercept and Infliximab for the Treatment of Rheumatoid Arthritis. Technology appraisal guidance no. 130. London: NICE; 2007.
82. National Institute for Health and Care Excellence. Certolizumab Pegol for the Treatment of Rheumatoid Arthritis. Technology appraisal guidance no. 186. London: NICE; 2010.
83. National Institute for Health and Care Excellence. NICE Provisionally Recommends New Drug for Rheumatoid Arthritis. Press release, 13 May 2011. URL: www. nice. org. uk/media/E4C/E5/2011081GolimumabForRAFAD. pdf (accessed April 2014).
84. Singh JA, Christensen R, Wells GA, Suarez-Almazor ME, Buchbinder R, Lopez-Olivo MA, et al. A network meta-analysis of randomized controlled trials of biologics for rheumatoid arthritis: a Cochrane overview. CMAJ 2009; 181: 787-96. http://dx. doi. org/10. 1503/cmaj. 091391.
85. Orme ME, Macgilchrist KS, Mitchell S, Spurden D, Bird A. Systematic review and network meta-analysis of combination and monotherapy treatments in disease-modifying antirheumatic drug-experienced patients with rheumatoid arthritis: analysis of American College of Rheumatology criteria scores 20, 50, and 70. Biologics 2012; 6: 429-64. http://dx. doi. org/10. 2147/BTT. S36707.
86. Singh JA, Wells GA, Christensen R, Tanjong Ghogomu E, Maxwell L, Macdonald JK, et al. Adverse effects of biologics: a network meta-analysis and Cochrane overview. Cochrane Database Syst Rev 2011; 2: CD008794. http://dx. doi. org/10. 1002/14651858. CD008794. pub2.
87. Svenson M, Geborek P, Saxne T, Bendtzen K. Monitoring patients treated with anti-TNF-alpha biopharmaceuticals: assessing serum infliximab and anti-infliximab antibodies. Rheumatology 2007; 46: 1828-34. http://dx. doi. org/10. 1093/rheumatology/kem261.
88. Strangfeld A, Hierse F, Kekow J, von Hinueber U, Tony HP, Dockhorn R, et al. Comparative effectiveness of tumour necrosis factor alpha inhibitors in combination with either methotrexate or leflunomide. Ann Rheum Dis 2009; 68: 1856-62. http://dx. doi. org/10. 1136/ard. 2008. 098467.
89. Smolen JS, Kay J, Doyle MK, Landewé R, Matteson EL, Wollenhaupt J, et al. Golimumab in patients with active rheumatoid arthritis after treatment with tumour necrosis factor alpha inhibitors (GO-AFTER study): a multicentre, randomised, double-blind, placebo-controlled, phase III trial. Lancet 2009; 374: 210-21. http://dx. doi. org/10. 1016/S0140-6736(09)60506-7.
90. Lloyd S, Bujkiewicz S, Wailoo AJ, Sutton AJ, Scott D. The effectiveness of anti-TNF-alpha therapies when used sequentially in rheumatoid arthritis patients: a systematic review and meta-analysis. Rheumatology 2010; 49: 2313-21. http://dx. doi. org/10. 1093/rheumatology/keq169.
91. Malottki K, Barton P, Tsourapas A, Uthman AO, Liu Z, Routh K, et al. Adalimumab, etanercept, infliximab, rituximab and abatacept for the treatment of rheumatoid arthritis after the failure of a tumour necrosis factor inhibitor: a systematic review and economic evaluation. Health Technol Assess 2011; 15(14). http://dx. doi. org/10. 3310/hta15140.
92. Bergman GJ, Hochberg MC, Boers M, Wintfeld N, Kielhorn A, Jansen JP. Indirect comparison of tocilizumab and other biologic agents in patients with rheumatoid arthritis and inadequate response to disease-modifying antirheumatic drugs. Semin Arthritis Rheum 2010; 39: 425-41. http://dx. doi. org/10. 1016/j. semarthrit. 2009. 12. 002.
93. Mertens M, Singh JA. Anakinra for rheumatoid arthritis: a systematic review. J Rheumatol 2009; 36: 1118-25. http://dx. doi. org/10. 3899/jrheum. 090074.
94. Lee YH, Bae SC, Song GG. The efficacy and safety of rituximab for the treatment of active rheumatoid arthritis: a systematic review and meta-analysis of randomized controlled trials. Rheumatol Int 2011; 31: 1493-9. http://dx. doi. org/10. 1007/s00296-010-1526-y.
95. Singh JA, Beg S, Lopez-Olivo MA. Tocilizumab for rheumatoid arthritis: a Cochrane systematic review. J Rheumatol 2011; 38: 10-20. http://dx. doi. org/10. 3899/jrheum. 100717.
96. Maxwell LJ, Singh JA. Abatacept for rheumatoid arthritis: a Cochrane systematic review. J Rheumatol 2010; 37: 234-45. http://dx. doi. org/10. 3899/jrheum. 091066.
97. Scott DL. Role of spleen tyrosine kinase inhibitors in the management of rheumatoid arthritis. Drugs 2011; 71: 1121-32. http://dx. doi. org/10. 2165/11591480-000000000-00000.
98. Riese RJ, Krishnaswami S, Kremer J. Inhibition of JAK kinases in patients with rheumatoid arthritis: scientific rationale and clinical outcomes. Best Pract Res Clin Rheumatol 2010; 24: 513-26. http://dx. doi. org/10. 1016/j. berh. 2010. 02. 003.
99. Traynor K. FDA approves tofacitinib for rheumatoid arthritis. Am J Health Syst Pharm 2012; 69: 2120. http://dx. doi. org/10. 2146/news120088.
100. Wienecke T, Gøtzsche PC. Paracetamol versus non-steroidal anti-inflammatory drugs for rheumatoid arthritis. Cochrane Database Syst Rev 2004; 1: CD003789.
101. Chen YF, Jobanputra P, Barton P, Bryan S, Fry-Smith A, Harris G, et al. Cyclooxygenase-2 selective non-steroidal anti-inflammatory drugs (etodolac, meloxicam, celecoxib, rofecoxib, etoricoxib, valdecoxib and lumiracoxib) for osteoarthritis and rheumatoid arthritis: a systematic review and economic evaluation. Health Technol Assess 2008; 12(11).
102. Haraoui B, Liu PP, Papp KA. Managing cardiovascular risk in patients with chronic inflammatory diseases. Clin Rheumatol 2012; 31: 585-94. http://dx. doi. org/10. 1007/s10067-011-1921-0.
103. Christie A, Jamtvedt G, Dahm KT, Moe RH, Haavardsholm EA, Hagen KB. Effectiveness of non-pharmacological and nonsurgical interventions for patients with rheumatoid arthritis: an overview of systematic reviews. Phys Ther 2007; 87: 1697-715. http://dx. doi. org/10. 2522/ptj. 20070039.
104. Hurkmans E, van der Giesen FJ, Vliet Vlieland TP, Schoones J, Van den Ende EC. Dynamic exercise programs (aerobic capacity and/or muscle strength training) in patients with rheumatoid arthritis. Cochrane Database Syst Rev 2009; 4: CD006853. http://dx. doi. org/10. 1002/14651858. CD006853. pub2.
105. Schoels M, Knevel R, Aletaha D, Bijlsma JW, Breedveld FC, Boumpas DT, et al. Evidence for treating rheumatoid arthritis to target: results of a systematic literature search. Ann Rheum Dis 2010; 69: 638-43. http://dx. doi. org/10. 1136/ard. 2009. 123976.
106. Haraoui B, Smolen JS, Aletaha D, Breedveld FC, Burmester G, Codreanu C, et al. Treating Rheumatoid Arthritis to Target: multinational recommendations assessment questionnaire. Ann Rheum Dis 2011; 70: 1999-2002. http://dx. doi. org/10. 1136/ard. 2011. 154179.
107. de Wit MP, Smolen JS, Gossec L, van der Heijde DM. Treating rheumatoid arthritis to target: the patient version of the international recommendations. Ann Rheum Dis 2011; 70: 891-5. http://dx. doi. org/10. 1136/ard. 2010. 146662.
108. Schoels M, Smolen JS. Treating rheumatoid arthritis to target: evidence-based recommendations for enhanced disease management. Rheumatol Clin 2012; 8: 1-2.
109. Sen D, Brasington R. Tight disease control in early RA. Rheum Dis Clin North Am 2012; 38: 327-43. http://dx. doi. org/10. 1016/j. rdc. 2012. 04. 004.
110. Welsing PM, Landewé RB, van Riel PL, Boers M, van Gestel AM, van der Linden S, et al. The relationship between disease activity and radiologic progression in patients with rheumatoid arthritis: a longitudinal analysis. Arthritis Rheum 2004; 50: 2082-93. http://dx. doi. org/10. 1002/art. 20350.
111. Grigor C, Capell H, Stirling A, McMahon AD, Lock P, Vallance R, et al. Effect of a treatment strategy of tight control for rheumatoid arthritis (the TICORA study): a single-blind randomised controlled trial. Lancet 2004; 364: 263-9. http://dx. doi. org/10. 1016/S0140-6736(04)16676-2.
112. Fransen J, Moens HB, Speyer I, van Riel PL. Effectiveness of systematic monitoring of rheumatoid arthritis disease activity in daily practice: a multicentre, cluster randomised controlled trial. Ann Rheum Dis 2005; 64: 1294-8. http://dx. doi. org/10. 1136/ard. 2004. 030924.
113. Verstappen SM, Jacobs JW, van der Veen MJ, Heurkens AH, Schenk Y, ter Borg EJ, et al. Intensive treatment with methotrexate in early rheumatoid arthritis: aiming for remission. Computer Assisted Management in Early Rheumatoid Arthritis (CAMERA, an open-label strategy trial). Ann Rheum Dis 2007; 66: 1443-9. http://dx. doi. org/10. 1136/ard. 2007. 071092.
114. Rantalaiho V, Korpela M, Laasonen L, Kautiainen H, Järvenpää S, Hannonen P, et al. Early combination disease-modifying antirheumatic drug therapy and tight disease control improve long-term radiologic outcome in patients with early rheumatoid arthritis: the 11-year results of the Finnish Rheumatoid Arthritis Combination Therapy trial. Arthritis Res Ther 2010; 12: R122. http://dx. doi. org/10. 1186/ar3060.
115. Ledingham J, Deighton C. Update on the British Society for Rheumatology guidelines for prescribing TNFalpha blockers in adults with rheumatoid arthritis (update of previous guidelines of April 2001). Rheumatology 2005; 44: 157-63. http://dx. doi. org/10. 1093/rheumatology/keh464.
116. Fautrel B, Flipo RM, Saraux A. Eligibility of rheumatoid arthritis patients for anti-TNF-alpha therapy according to the 2005 recommendations of the French and British Societies for Rheumatology. Rheumatology 2008; 47: 1698-703. http://dx. doi. org/10. 1093/rheumatology/ken348.
117. Smolen JS, Landewé R, Breedveld FC, Dougados M, Emery P, Gaujoux-Viala C, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs. Ann Rheum Dis 2010; 69: 964-75. http://dx. doi. org/10. 1136/ard. 2009. 126532.
118. Singh JA, Furst DE, Bharat A, Curtis JR, Kavanaugh AF, Kremer JM, et al. 2012 update of the 2008 American College of Rheumatology recommendations for the use of disease-modifying antirheumatic drugs and biologic agents in the treatment of rheumatoid arthritis. Arthritis Care Res 2012; 64: 625-39. http://dx. doi. org/10. 1002/acr. 21641.
119. British Society for Rheumatology. Guidelines for Prescribing TNF-α Blockers in Adults with Rheumatoid Arthritis. London: British Society for Rheumatology; 2001. URL: www. rheumatology. org. uk (accessed April 2014).
120. Deighton C, Hyrich K, Ding T, Ledingham J, Lunt M, Luqmani R, et al. BSR and BHPR rheumatoid arthritis guidelines on eligibility criteria for the first biological therapy. Rheumatology 2010; 49: 1197-9. http://dx. doi. org/10. 1093/rheumatology/keq006a.
121. Jönsson B, Kobelt G, Smolen J. The burden of rheumatoid arthritis and access to treatment: uptake of new therapies. Eur J Health Econ 2008; 8(Suppl. 2): S61-86. http://dx. doi. org/10. 1007/s10198-007-0089-7.
122. Orlewska E, Ancuta I, Anic B, Codrenau C, Damjanov N, Djukic P, et al. Access to biologic treatment for rheumatoid arthritis in Central and Eastern European (CEE) countries. Med Sci Monit 2011; 17: SR1-13. http://dx. doi. org/10. 12659/MSM. 881697.
123. Hoebert JM, Mantel-Teeuwisse AK, van Dijk L, Bijlsma JW, Leufkens HG. Do rheumatoid arthritis patients have equal access to treatment with new medicines?: tumour necrosis factor-alpha inhibitors use in four European countries. Health Policy 2012; 104: 76-83. http://dx. doi. org/10. 1016/j. healthpol. 2011. 10. 011.
124. Laires PA, Exposto F, Mesquita R, Martins AP, Cunha-Miranda L, Fonseca JE. Patients' access to biologics in rheumatoid arthritis: a comparison between Portugal and other European countries. Eur J Health Econ 2013; 14: 875-85. http://dx. doi. org/10. 1007/s10198-012-0432-5.
125. National Institute for Health and Care Excellence. Assumptions Used in Estimating a Population Benchmark. 16 October 2012. URL: www. nice. org. uk/usingguidance/commissioningguides/biologicaltherapies/AssumptionsUsedInEstimatingAPopulationBenchmark. jsp (accessed April 2012).
126. Marra CA, Bansback N, Anis AH, Shojania K. Introduction to economic modelling for clinical rheumatologists: application to biologic agents in rheumatoid arthritis. Clin Rheumatol 2011; 30(Suppl. 1): S9-18. http://dx. doi. org/10. 1007/s10067-010-1635-8.
127. Madan J, Ades AE, Welton NJ. An overview of models used in economic analyses of biologic therapies for arthritis-from current diversity to future consensus. Rheumatology 2011; 50(Suppl. 4): iv10-18. http://dx. doi. org/10. 1093/rheumatology/ker240.
128. Schoels M, Wong J, Scott DL, Zink A, Richards P, Landewé R, et al. Economic aspects of treatment options in rheumatoid arthritis: a systematic literature review informing the EULAR recommendations for the management of rheumatoid arthritis. Ann Rheum Dis 2010; 69: 995-1003. http://dx. doi. org/10. 1136/ard. 2009. 126714.
129. Brennan A, Bansback N, Nixon R, Madan J, Harrison M, Watson K, et al. Modelling the cost effectiveness of TNF-alpha antagonists in the management of rheumatoid arthritis: results from the British Society for Rheumatology Biologics Registry. Rheumatology 2007; 46: 1345-54. http://dx. doi. org/10. 1093/rheumatology/kem115.
130. van der Velde G, Pham B, Machado M, Ieraci L, Witteman W, Bombardier C, et al. Cost-effectiveness of biologic response modifiers compared to disease-modifying antirheumatic drugs for rheumatoid arthritis: a systematic review. Arthritis Care Res 2011; 63: 65-78. http://dx. doi. org/10. 1002/acr. 20338.
131. Hyrich KL, Watson KD, Silman AJ, Symmons DP. Predictors of response to anti-TNF-alpha therapy among patients with rheumatoid arthritis: results from the British Society for Rheumatology Biologics Register. Rheumatology 2006; 45: 1558-65. http://dx. doi. org/10. 1093/rheumatology/kel149.
132. Smith N, Ding T, Butt S, Gadsby K, Deighton C. The importance of the baseline Disease Activity Score 28 in determining responders and non-responders to anti-TNF in UK clinical practice. Rheumatology 2008; 47: 1389-91. http://dx. doi. org/10. 1093/rheumatology/ken233.
133. Desroches M, Louis G, Gleizes A, Krzysiek R, Emilie D. Treatment failure with antagonists of TNF-α: mechanisms and implications for the care of patients. Eur Cytokine Netw 2010; 21: 226-31. http://dx. doi. org/10. 1684/ecn. 2010. 0212.
134. McGeough CM, Berrar D, Wright G, Mathews C, Gilmore P, Cunningham RT, et al. Killer immunoglobulin-like receptor and human leukocyte antigen-C genotypes in rheumatoid arthritis primary responders and non-responders to anti-TNF-α therapy. Rheumatol Int 2012; 32: 1647-53. http://dx. doi. org/10. 1007/s00296-011-1838-6.
135. Ma MH, Kingsley GH, Scott DL. A systematic comparison of combination DMARD therapy and tumour necrosis inhibitor therapy with methotrexate in patients with early rheumatoid arthritis. Rheumatology 2010; 49: 91-8. http://dx. doi. org/10. 1093/rheumatology/kep331.
136. Ma MHY, Cope AC, Scott DL. Safety of combination therapies in early RA: a systematic comparison between combination DMARDs and TNF inihibitors with methotrexate. Int J Clin Rheumatol 2010; 5: 547-554. http://dx. doi. org/10. 2217/ijr. 10. 44.
137. Verhoeven AC, Boers M, Tugwell P. Combination therapy in rheumatoid arthritis: updated systematic review. Br J Rheumatol 1998; 37: 612-19. http://dx. doi. org/10. 1093/rheumatology/37. 6. 612.
138. Chen YF, Jobanputra P, Barton P, Jowett S, Bryan S, Clark W, et al. A systematic review of the effectiveness of adalimumab, etanercept and infliximab for the treatment of rheumatoid arthritis in adults and an economic evaluation of their cost-effectiveness. Health Technol Assess 2006; 10(42).
139. Kristensen LE, Christensen R, Bliddal H, Geborek P, Danneskiold-Samsøe B, Saxne T. The number needed to treat for adalimumab, etanercept, and infliximab based on ACR50 response in three randomized controlled trials on established rheumatoid arthritis: a systematic literature review. Scand J Rheumatol 2007; 36: 411-17. http://dx. doi. org/10. 1080/03009740701607067.
140. Donahue KE, Gartlehner G, Jonas DE, Lux LJ, Thieda P, Jonas BL, et al. Systematic review: comparative effectiveness and harms of disease-modifying medications for rheumatoid arthritis. Ann Intern Med 2008; 148: 124-34. http://dx. doi. org/10. 7326/0003-4819-148-2-200801150-00192.
141. Katchamart W, Trudeau J, Phumethum V, Bombardier C. Efficacy and toxicity of methotrexate (MTX) monotherapy versus MTX combination therapy with non-biological disease-modifying antirheumatic drugs in rheumatoid arthritis: a systematic review and meta-analysis. Ann Rheum Dis 2009; 68: 1105-12. http://dx. doi. org/10. 1136/ard. 2008. 099861.
142. Katchamart W, Trudeau J, Phumethum V, Bombardier C. Methotrexate monotherapy versus methotrexate combination therapy with non-biologic disease modifying anti-rheumatic drugs for rheumatoid arthritis. Cochrane Database Syst Rev 2010; 4: CD008495. http://dx. doi. org/10. 1002/14651858. CD008495.
143. Nam JL, Winthrop KL, van Vollenhoven RF, Pavelka K, Valesini G, Hensor EM, et al. Current evidence for the management of rheumatoid arthritis with biological disease-modifying antirheumatic drugs: a systematic literature review informing the EULAR recommendations for the management of RA. Ann Rheum Dis 2010; 69: 976-86. http://dx. doi. org/10. 1136/ard. 2009. 126573.
144. Aaltonen KJ, Virkki LM, Malmivaara A, Konttinen YT, Nordström DC, Blom M. Systematic review and meta-analysis of the efficacy and safety of existing TNF blocking agents in treatment of rheumatoid arthritis. PLoS One 2012; 7: e30275. http://dx. doi. org/10. 1371/journal. pone. 0030275.
145. Scott DL, Strand V. The effects of disease-modifying anti-rheumatic drugs on the Health Assessment Questionnaire score. Lessons from the leflunomide clinical trials database. Rheumatology 2002; 41: 899-909. http://dx. doi. org/10. 1093/rheumatology/41. 8. 899.
146. Strand V, Cohen S, Crawford B, Smolen JS, Scott DL; Leflunomide Investigators Groups. Patient-reported outcomes better discriminate active treatment from placebo in randomized controlled trials in rheumatoid arthritis. Rheumatology 2004; 43: 640-7. http://dx. doi. org/10. 1093/rheumatology/keh140.
147. Goekoop-Ruiterman YP, de Vries-Bouwstra JK, Allaart CF, van Zeben D, Kerstens PJ, Hazes JM, et al. Clinical and radiographic outcomes of four different treatment strategies in patients with early rheumatoid arthritis (the BeSt study): a randomized, controlled trial. Arthritis Rheum 2005; 52: 3381-90. http://dx. doi. org/10. 1002/art. 21405.
148. British Medical Association and Royal Pharmaceutical Society of Great Britain. British National Formulary. No. 54, September 2007. London: BMA and RPS; 2007.
149. British Society for Rheumatology. National Guidelines for the Monitoring of Second Line Drugs. July 2000. URL: www. rheumatology. org. uk/includes/documents/cm_docs/2009/m/monitoring_second_line_drugs. pdf (accessed August 2014).
150. Chakravarty K, McDonald H, Pullar T, Taggart A, Chalmers R, Oliver S, et al. BSR/BHPR guideline for disease-modifying anti-rheumatic drug (DMARD) therapy in consultation with the British Association of Dermatologists. Rheumatology 2008; 47: 924-5. http://dx. doi. org/10. 1093/rheumatology/kel216a.
151. Ding T, Ledingham J, Luqmani R, Westlake S, Hyrich K, Lunt M, et al. BSR and BHPR rheumatoid arthritis guidelines on safety of anti-TNF therapies. Rheumatology 2010; 49: 2217-19. http://dx. doi. org/10. 1093/rheumatology/keq249a.
152. Scott DL, Garrood T. Quality of life measures: use and abuse. Baillieres Best Pract Res Clin Rheumatol 2000; 14: 663-87. http://dx. doi. org/10. 1053/berh. 2000. 0106.
153. Bruce B, Fries JF. The Stanford Health Assessment Questionnaire: dimensions and practical applications. Health Qual Life Outcomes 2003; 1: 20. http://dx. doi. org/10. 1186/1477-7525-1-20.
154. Wolfe F. A reappraisal of HAQ disability in rheumatoid arthritis. Arthritis Rheum 2000; 43: 2751-61. http://dx. doi. org/10. 1002/1529-0131(200012)43: 12<2751:: AID-ANR15>3. 0. CO; 2-6.
155. The EuroQol Group. EuroQol-a new facility for the measurement of health-related quality of life. Health Policy 1990; 16: 199-208. http://dx. doi. org/10. 1016/0168-8510(90)90421-9.
156. Ware JE Jr. SF-36 health survey update. Spine 2000; 25: 3130-9. http://dx. doi. org/10. 1097/00007632-200012150-00008.
157. Khanna D, Tsevat J. Health-related quality of life-an introduction. Am J Manag Care 2007; 13(Suppl. 9): S218-23.
158. Linde L, Sørensen J, Ostergaard M, Hørslev-Petersen K, Hetland ML. Health-related quality of life: validity, reliability, and responsiveness of SF-36, 15D, EQ-5D, RAQoL, and HAQ in patients with rheumatoid arthritis. J Rheumatol 2008; 35: 1528-37.
159. Wolfe F, Michaud K, Li T, Katz RS. EQ-5D and SF-36 quality of life measures in systemic lupus erythematosus: comparisons with rheumatoid arthritis, noninflammatory rheumatic disorders, and fibromyalgia. J Rheumatol 2010; 37: 296-304. http://dx. doi. org/10. 3899/jrheum. 090778.
160. Oude Voshaar MA, ten Klooster PM, Taal E, van de Laar MA. Measurement properties of physical function scales validated for use in patients with rheumatoid arthritis: a systematic review of the literature. Health Qual Life Outcomes 2011; 9: 99. http://dx. doi. org/10. 1186/1477-7525-9-99.
161. Scott DL, Smith C, Kingsley G. Joint damage and disability in rheumatoid arthritis: an updated systematic review. Clin Exp Rheumatol 2003; 21(Suppl. 31): S20-7.
162. Larsens A, Dale K, Eek M. Radiographic evaluation of rheumatoid arthritis and related conditions by standard reference films. Acta Radiol Diagn 1977; 8: 481-91.
163. Scott DL, Houssien DA, Laassonen L. Proposed modification to Larsen's scoring methods for hand and wrist radiographs. Br J Rheumatol 1995; 34: 56. http://dx. doi. org/10. 1093/rheumatology/34. 1. 56.
164. Prevoo ML, van'T Hof M, Kuper HH, Van Leeuwen MA, Van de Putte LB, Van Riel PL. Modified disease activity scores that include twenty-eight-joint counts. Development and validation in a prospective longitudinal study of patients with RA. Arthritis Rheum 1995; 38: 44-8. http://dx. doi. org/10. 1002/art. 1780380107.
165. Lassere MN, Johnson KR, Boers M, Carlton K, Day RO, de Wit M, et al. Standardized assessment of adverse events in rheumatology clinical trials: summary of the OMERACT 7 drug safety module update. J Rheumatol 2005; 32: 2037-41.
166. European Medicines Agency. Guideline on Clinical Investigation of Medicinal Products other than NSAIDs for Treatment of Rheumatoid Arthritis. 2011. URL: www. ema. europa. eu/ema/index. jsp (accessed April 2014).
167. US Food and Drug Administration. Guidance for Industry. Rheumatoid Arthritis: Developing Drug Products for Treatment. 2013. URL: www. fda. gov/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/default. htm (accessed April 2014).
168. Beecham, Knapp M. Costing psychiatric interventions. In Thornicroft G, Brewin C, Wing JK, editors. Measuring Mental Health Needs. London: Gaskell; 1992. pp. 203-27.
169. Hurley MV, Walsh NE, Mitchell H, Nicholas J, Patel A. Long-term outcomes and costs of an integrated rehabilitation program for chronic knee pain: a pragmatic, cluster randomized, controlled trial. Arthritis Care Res 2012; 64: 238-47. http://dx. doi. org/10. 1002/acr. 20642.
170. Lipsky PE, van der Heijde D, St Clair E, Furst DE, Breedveld FC, Kalden JR, et al. Infliximab and methotrexate in the treatment of rheumatoid arthritis. Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy Study Group. N Engl J Med 2000; 343: 1594-602. http://dx. doi. org/10. 1056/NEJM200011303432202.
171. Choy EH, Smith CM, Farewell V, Walker D, Hassell A, Chau L, et al. Factorial randomised controlled trial of glucocorticoids and combination disease modifying drugs in early rheumatoid arthritis. Ann Rheum Dis 2008; 67: 656-63. http://dx. doi. org/10. 1136/ard. 2007. 076299.
172. Wells GA, Tugwell P, Kraag GR, Baker PR, Groh J, Redelmeier DA. Minimum important difference between patients with rheumatoid arthritis: the patient's perspective. J Rheumatol 1993; 20: 557-60.
173. Redelmeier DA, Lorig K. Assessing the clinical importance of symptomatic improvements. An illustration in rheumatology. Arch Intern Med 1993; 153: 1337-42. http://dx. doi. org/10. 1001/archinte. 1993. 00410110045008.
174. Kosinski M, Zhao SZ, Dedhiya S, Osterhaus JT, Ware JE. Determining minimally important changes in generic and disease-specific health-related quality of life questionnaires in clinical trials of rheumatoid arthritis. Arthritis Rheum 2000; 43: 1478-87. http://dx. doi. org/10. 1002/1529-0131 (200007)43: 7<1478:: AID-ANR10>3. 0. CO; 2-M.
175. Strand V, Tugwell P, Bombardier C, Maetzel A, Bombardier C, Crawford B, et al. Function and health-related quality of life: results from a randomized controlled trial of leflunomide versus methotrexate or placebo in patients with active rheumatoid arthritis. Leflunomide Rheumatoid Arthritis Investigators Group. Arthritis Rheum 1999; 42: 1870-8. http://dx. doi. org/10. 1002/1529-0131(199909)42: 9<1870:: AID-ANR11>3. 0. CO; 2-D.
176. White IR, Royston P, Wood AM. Multiple imputation using chained equations: issues and guidance for practice. Stat Med 2011; 30: 377-99. http://dx. doi. org/10. 1002/sim. 4067.
177. Rubin DB. Inference and missing data. Biometrika 1976; 63: 581-90. http://dx. doi. org/10. 1093/biomet/63. 3. 581.
178. Little RJA, Rubin DB. Statistical Analysis with Missing Data, 2nd edn. Hoboken, NJ: John Wiley; 2002. http://dx. doi. org/10. 1002/9781119013563.
179. Schafer JL. Analysis of Incomplete Multivariate Data, 1st edn. London: Chapman and Hall; 1997. http://dx. doi. org/10. 1201/9781439821862.
180. R Development Core Team. R: A language and environment for statistical computing. Vienna, Austria: R Foundation for Statistical Computing; 2012. URL: www. R-project. org (accessed August 2014).
181. Diggle P, Farewell D, Henderson R. Analysis of longitudinal data with drop-out: objectives, assumptions and a proposal. J R Stat Soc C Appl Stat 2007; 56: 499-550. http://dx. doi. org/10. 1111/j. 1467-9876. 2007. 00590. x.
182. Brazier J, Roberts J, Deverill M. The estimation of a preference-based measure of health from the SF-36. J Health Econ 2002; 21: 271-92. http://dx. doi. org/10. 1016/S0167-6296(01)00130-8.
183. Dolan P, Gudex C, Kind P, Williams A. A Social Tariff for EuroQol: Results from a UK Population Survey. York: University of York; 1995.
184. Manca A, Hawkins N, Schulpher MJ. Estimating mean QALYs in trial-based cost-effectiveness analysis: the importance of controlling for baseline utility. Health Econ 2005; 14: 487-96. http://dx. doi. org/10. 1002/hec. 944.
185. Assmann SF, Pocock SJ, Enos LE, Kasten LE. Subgroup analysis and other (mis)uses of baseline data in clinical trials. Lancet 2000; 355: 1064-9. http://dx. doi. org/10. 1016/S0140-6736(00)02039-0.
186. Briggs AH. A Bayesian approach to stochastic cost-effectiveness analysis. Health Econ 1999; 8: 257-61. http://dx. doi. org/10. 1002/(SICI)1099-1050(199905)8: 3<257:: AID-HEC427>3. 0. CO; 2-E.
187. Moher D, Liberati A, Tetzlaff J, Altman DG, The PRISMA group. Preferred Reporting Items for Systematic Reviews and Meta-Analyses: the PRISMA statement PLoS Med 2009; 6: e1000097. http://dx. doi. org/10. 1371/journal. pmed. 1000097.
188. Viswanathan M, Ansari MT, Berkman ND, Chang S, Hartling L, McPheeters LM, et al. Assessing the Risk of Bias of Individual Studies in Systematic Reviews of Health Care Interventions. Methods Guide for Comparative Effectiveness Review. AHRQ Publication No. 12-EHC047-EF. Rockville, MD: Agency for Healthcare Research and Quality; 2012.
189. DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials 1986; 7: 177-88. http://dx. doi. org/10. 1016/0197-2456(86)90046-2.
190. Hardy RJ, Thompson SG. Detecting and describing heterogeneity in meta-analysis. Stat Med 1998; 17: 841-56. http://dx. doi. org/10. 1002/(SICI)1097-0258(19980430)17: 8<841:: AID-SIM781>3. 0. CO; 2-D.
191. Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ 2003; 327: 557-60. http://dx. doi. org/10. 1136/bmj. 327. 7414. 557.
192. Haagsma CJ, van Riel PL, de Jong AJ, van de Putte LB. Combination of sulphasalazine and methotrexate versus the single components in early rheumatoid arthritis: a randomized, controlled, double-blind, 52 week clinical trial. Br J Rheumatol 1997; 36: 1082-8. http://dx. doi. org/10. 1093/rheumatology/36. 10. 1082.
193. van den Borne BE, Landewé RB, Goei The HS, Rietveld JH, Zwinderman AH, Bruyn GA, et al. Combination therapy in recent onset rheumatoid arthritis: a randomized double blind trial of the addition of low dose cyclosporine to patients treated with low dose chloroquine. J Rheumatol 1998; 25: 1493-8.
194. Dougados M, Combe B, Cantagrel A, Goupille P, Olive P, Schattenkirchner M, et al. Combination therapy in early rheumatoid arthritis: a randomised, controlled, double blind 52 week clinical trial of sulphasalazine and methotrexate compared with the single components. Ann Rheum Dis 1999; 58: 220-5. http://dx. doi. org/10. 1136/ard. 58. 4. 220.
195. Mottonen T, Hannonen P, Leirisalo-Repo M, Nissilä M, Kautiainen H, Korpela M, et al. Comparison of combination therapy with single-drug therapy in early rheumatoid arthritis: a randomised trial. FIN-RACo trial group. Lancet 1999; 353: 1568-73. http://dx. doi. org/10. 1016/S0140-6736(98)08513-4.
196. Proudman SM, Conaghan PG, Richardson C, Griffiths B, Green MJ, McGonagle D, et al. Treatment of poor-prognosis early rheumatoid arthritis. A randomized study of treatment with methotrexate, cyclosporin A, and intraarticular corticosteroids compared with sulfasalazine alone. Arthritis Rheum 2000; 43: 1809-19. http://dx. doi. org/10. 1002/1529-0131(200008)43: 8<1809:: AID-ANR17>3. 0. CO; 2-D.
197. Ferraccioli GF, Gremese E, Tomietto P, Favret G, Damato R, Di Poi E. Analysis of improvements, full responses, remission and toxicity in rheumatoid patients treated with step-up combination therapy (methotrexate, cyclosporin A, sulphasalazine) or monotherapy for three years. Rheumatology 2002; 41: 892-8. http://dx. doi. org/10. 1093/rheumatology/41. 8. 892.
198. Gerards AH, Landewe RB, Prins AP, Bruyn GA, Goei Thé HS, Laan RF, et al. Cyclosporin A monotherapy versus cyclosporin A and methotrexate combination therapy in patients with early rheumatoid arthritis. Ann Rheum Dis 2003; 62: 291-6. http://dx. doi. org/10. 1136/ard. 62. 4. 291.
199. Marchesoni A, Battafarano N, Arreghini M, Panni B, Gallazzi M, Tosi S. Radiographic progression in early rheumatoid arthritis: a 12-month randomized controlled study comparing the combination of cyclosporin and methotrexate with methotrexate alone. Rheumatology 2003; 42: 1545-9. http://dx. doi. org/10. 1093/rheumatology/keg394.
200. Capell HA, Madhok R, Hunter JA, Porter D, Morrison E, Larkin J, et al. Lack of radiological and clinical benefit over two years of low dose prednisolone for rheumatoid arthritis: results of a randomised controlled trial. Ann Rheum Dis 2004; 63: 797-803. http://dx. doi. org/10. 1136/ard. 2003. 014050.
201. Miranda JM, Alvarez-Nemegyei J, Saavedra MA, Terán L, Galván-Villegas F, García-Figueroa J, et al. A randomized, double-blind, multicenter, controlled clinical trial of cyclosporine plus chloroquine vs. cyclosporine plus placebo in early-onset rheumatoid arthritis. Arch Med Res 2004; 35: 36-42. http://dx. doi. org/10. 1016/j. arcmed. 2003. 07. 008.
202. Ichikawa Y, Saito T, Yamanaka H, Akizuki M, Kondo H, Kobayashi S, et al. Therapeutic effects of the combination of methotrexate and bucillamine in early rheumatoid arthritis: a multicenter, double-blind, randomized controlled study. Mod Rheumatol 2005; 15: 323-8. http://dx. doi. org/10. 3109/s10165-005-0420-z.
203. Sarzi-Puttini P, D'Ingianna E, Fumagalli M, Scarpellini M, Fiorini T, Chérié-Lignière EL, et al. An open, randomized comparison study of cyclosporine A, cyclosporine A + methotrexate and cyclosporine A + hydroxychloroquine in the treatment of early severe rheumatoid arthritis. Rheumatol Int 2005; 25: 15-22 http://dx. doi. org/10. 1007/s00296-003-0384-2.
204. Svensson B, Boonen A, Albertsson K, van der Heijde D, Keller C, Hafström I. Low-dose prednisolone in addition to the initial disease-modifying antirheumatic drug in patients with early active rheumatoid arthritis reduces joint destruction and increases the remission rate: a two-year randomized trial. Arthritis Rheum 2005; 52: 3360-70. http://dx. doi. org/10. 1002/art. 21298.
205. Wassenberg S, Rau R, Steinfeld P, Zeidler H. Very low-dose prednisolone in early rheumatoid arthritis retards radiographic progression over two years: a multicenter, double-blind, placebo-controlled trial. Arthritis Rheum 2005; 52: 3371-80. http://dx. doi. org/10. 1002/art. 21421.
206. Hetland ML, Stengaard-Pedersen K, Junker P, Lottenburger T, Ellingsen T, Andersen LS, et al. Combination treatment with methotrexate, cyclosporine, and intraarticular betamethasone compared with methotrexate and intraarticular betamethasone in early active rheumatoid arthritis: an investigator-initiated, multicenter, randomized, double-blind, parallel-group, placebo-controlled study. Arthritis Rheum 2006; 54: 1401-9. http://dx. doi. org/10. 1002/art. 21796.
207. O'Dell JR, Elliott JR, Mallek JA, Mikuls TR, Weaver CA, Glickstein S, et al. Treatment of early seropositive rheumatoid arthritis: doxycycline plus methotrexate versus methotrexate alone. Arthritis Rheum 2006; 54: 621-7. http://dx. doi. org/10. 1002/art. 21620.
208. Breedveld FC, Emery P, Keystone E, Patel K, Furst DE, Kalden JR, et al. Infliximab in active early rheumatoid arthritis. Ann Rheum Dis 2004; 63: 149-55. http://dx. doi. org/10. 1136/ard. 2003. 013961.
209. St Clair EW, van der Heijde DM, Smolen JS, Maini RN, Bathon JM, Emery P, et al. Combination of infliximab and methotrexate therapy for early rheumatoid arthritis: a randomized, controlled trial. Arthritis Rheum 2004; 50: 3432-43. http://dx. doi. org/10. 1002/art. 20568.
210. Taylor PC, Steuer A, Gruber J, Cosgrove DO, Blomley MJ, Marsters PA, et al. Comparison of ultrasonographic assessment of synovitis and joint vascularity with radiographic evaluation in a randomized, placebo-controlled study of infliximab therapy in early rheumatoid arthritis. Arthritis Rheum 2004; 50: 1107-16. http://dx. doi. org/10. 1002/art. 20123.
211. Quinn MA, Conaghan PG, O'Connor PJ, Karim Z, Greenstein A, Brown A, et al. Very early treatment with infliximab in addition to methotrexate in early, poor-prognosis rheumatoid arthritis reduces magnetic resonance imaging evidence of synovitis and damage, with sustained benefit after infliximab withdrawal: results from a twelve-month randomized, double-blind, placebo-controlled trial. Arthritis Rheum 2005; 52: 27-35. http://dx. doi. org/10. 1002/art. 20712.
212. Breedveld FC, Weisman MH, Kavanaugh AF, Cohen SB, Pavelka K, van Vollenhoven R, et al. The PREMIER study: a multicenter, randomized, double-blind clinical trial of combination therapy with adalimumab plus methotrexate versus methotrexate alone or adalimumab alone in patients with early, aggressive rheumatoid arthritis who had not had previous methotrexate treatment. Arthritis Rheum 2006; 54: 26-37. http://dx. doi. org/10. 1002/art. 21519.
213. Durez P, Malghem J, Nzeusseu Toukap A, Depresseux G, Lauwerys BR, Westhovens R, et al. Treatment of early rheumatoid arthritis: a randomized magnetic resonance imaging study comparing the effects of methotrexate alone, methotrexate in combination with infliximab, and methotrexate in combination with intravenous pulse methylprednisolone. Arthritis Rheum 2007; 56: 3919-27. http://dx. doi. org/10. 1002/art. 23055.
214. Emery P, Breedveld FC, Hall S, Durez P, Chang DJ, Robertson D, et al. Comparison of methotrexate monotherapy with a combination of methotrexate and etanercept in active, early, moderate to severe rheumatoid arthritis (COMET): a randomised, double-blind, parallel treatment trial. Lancet 2008; 372: 375-82. http://dx. doi. org/10. 1016/S0140-6736(08)61000-4.
215. Soubrier M, Puechal X, Sibilia J, Mariette X, Meyer O, Combe B, et al. Evaluation of two strategies (initial methotrexate monotherapy vs its combination with adalimumab) in management of early active rheumatoid arthritis: data from the GUEPARD trial. Rheumatology 2009; 48: 1429-34 http://dx. doi. org/10. 1093/rheumatology/kep261.
216. Detert J, Bastian H, Listing J, Weiß A, Wassenberg S, Liebhaber A, et al. Induction therapy with adalimumab plus methotrexate for 24 weeks followed by methotrexate monotherapy up to week 48 versus methotrexate therapy alone for DMARD-naive patients with early rheumatoid arthritis: HIT HARD, an investigator-initiated study. Ann Rheum Dis 2013; 72: 844-50. http://dx. doi. org/10. 1136/annrheumdis-2012-201612.
217. Kavanaugh A, Fleischmann RM, Emery P, Kupper H, Redden L, Guerette B, et al. Clinical, functional and radiographic consequences of achieving stable low disease activity and remission with adalimumab plus methotrexate or methotrexate alone in early rheumatoid arthritis: 26-week results from the randomised, controlled OPTIMA study. Ann Rheum Dis 2013; 72: 64-71. http://dx. doi. org/10. 1136/annrheumdis-2011-201247.
218. van Vollenhoven RF, Ernestam S, Geborek P, Petersson IF, Cöster L, Waltbrand E, et al. Addition of infliximab compared with addition of sulfasalazine and hydroxychloroquine to methotrexate in patients with early rheumatoid arthritis (Swefot trial): 1-year results of a randomised trial. Lancet 2009; 374: 459-66. http://dx. doi. org/10. 1016/S0140-6736(09)60944-2.
219. Moreland LW, O'Dell JR, Paulus HE, Curtis JR, Bathon JM, St Clair EW, et al. TEAR Investigators. A randomized comparative effectiveness study of oral triple therapy versus etanercept plus methotrexate in early aggressive rheumatoid arthritis: the treatment of Early Aggressive Rheumatoid Arthritis Trial. Arthritis Rheum 2012; 64: 2824-35. http://dx. doi. org/10. 1002/art. 34498.
220. Goekoop-Ruiterman YP, de Vries-Bouwstra JK, Allaart CF, van Zeben D, Kerstens PJ, Hazes JM, et al. Comparison of treatment strategies in early rheumatoid arthritis: a randomized trial. Ann Intern Med 2007; 146: 406-15. http://dx. doi. org/10. 7326/0003-4819-146-6-200703200-00005.
221. van Vollenhoven RF, Geborek P, Forslind K, Albertsson K, Ernestam S, Petersson IF, et al. Swefot study group. Conventional combination treatment versus biological treatment in methotrexate-refractory early rheumatoid arthritis: 2 year follow-up of the randomised, non-blinded, parallel-group Swefot trial. Lancet 2012; 379: 1712-20. http://dx. doi. org/10. 1016/S0140-6736(12)60027-0.
222. Ferraz MB, Pinheiro GR, Helfenstein M, Albuquerque E, Rezende C, Roimicher L, et al. Combination therapy with methotrexate and chloroquine in rheumatoid arthritis. A multicenter randomized placebo-controlled trial. Scand J Rheumatol 1994; 23: 231-6. http://dx. doi. org/10. 3109/03009749409103721.
223. Willkens RF, Sharp JT, Stablein D, Marks C, Wortmann R. Comparison of azathioprine, methotrexate, and the combination of the two in the treatment of rheumatoid arthritis. A forty-eight-week controlled clinical trial with radiologic outcome assessment. Arthritis Rheum 1995; 38: 1799-806. http://dx. doi. org/10. 1002/art. 1780381213.
224. Bendix G, Bjelle A. Adding low-dose cyclosporin A to parenteral gold therapy in rheumatoid arthritis: a double-blind placebo-controlled study. Br J Rheumatol 1996; 35: 1142-9. http://dx. doi. org/10. 1093/rheumatology/35. 11. 1142.
225. Kremer JM, Genovese MC, Cannon GW, Caldwell JR, Cush JJ, Furst DE, et al. Concomitant leflunomide therapy in patients with active rheumatoid arthritis despite stable doses of methotrexate. A randomized, double-blind, placebo-controlled trial. Ann Intern Med 2002; 137: 726-33. http://dx. doi. org/10. 7326/0003-4819-137-9-200211050-00007.
226. Dougados M, Emery P, Lemmel EM, Zerbini CA, Brin S, van Riel P. When a DMARD fails, should patients switch to sulfasalazine or add sulfasalazine to continuing leflunomide? Ann Rheum Dis 2005; 64: 44-51. http://dx. doi. org/10. 1136/ard. 2003. 016709.
227. Lehman AJ, Esdaile JM, Klinkhoff AV, Grant E, Fitzgerald A, Canvin J; METGO study group. A 48-week, randomized, double-blind, double-observer, placebo-controlled multicenter trial of combination methotrexate and intramuscular gold therapy in rheumatoid arthritis: results of the METGO study. Arthritis Rheum 2005; 52: 1360-70. http://dx. doi. org/10. 1002/art. 21018.
228. Karanikolas G, Charalambopoulos D, Andrianakos A, Antoniades C, Katsilambros N. Combination of cyclosporine and leflunomide versus single therapy in severe rheumatoid arthritis. J Rheumatol 2006; 33: 486-9.
229. Capell HA, Madhok R, Porter DR, Munro RA, McInnes IB, Hunter JA, et al. Combination therapy with sulfasalazine and methotrexate is more effective than either drug alone in patients with rheumatoid arthritis with a suboptimal response to sulfasalazine: results from the double-blind placebo-controlled MASCOT study. Ann Rheum Dis 2007; 66: 235-41. http://dx. doi. org/10. 1136/ard. 2006. 057133.
230. Weinblatt ME, Kremer JM, Bankhurst AD, Bulpitt KJ, Fleischmann RM, Fox RI, et al. A trial of etanercept, a recombinant tumor necrosis factor receptor: Fc fusion protein, in patients with rheumatoid arthritis receiving methotrexate. N Engl J Med 1999; 340: 253-9. http://dx. doi. org/10. 1056/NEJM199901283400401.
231. Weinblatt ME, Keystone EC, Furst DE, Moreland LW, Weisman MH, Birbara CA, et al. Adalimumab, a fully human anti-tumor necrosis factor alpha monoclonal antibody, for the treatment of rheumatoid arthritis in patients taking concomitant methotrexate: the ARMADA trial. Arthritis Rheum 2003; 48: 35-45. http://dx. doi. org/10. 1002/art. 10697.
232. Klareskog L, van der Heijde D, de Jager JP, Gough A, Kalden J, Malaise M, et al. Therapeutic effect of the combination of etanercept and methotrexate compared with each treatment alone in patients with rheumatoid arthritis: double-blind randomised controlled trial. Lancet 2004; 363: 675-81. http://dx. doi. org/10. 1016/S0140-6736(04)15640-7.
233. Kay J, Matteson EL, Dasgupta B, Nash P, Durez P, Hall S, et al. Golimumab in patients with active rheumatoid arthritis despite treatment with methotrexate: a randomized, double-blind, placebo-controlled, dose-ranging study. Arthritis Rheum 2008; 58: 964-75. http://dx. doi. org/10. 1002/art. 23383.
234. Keystone E, Heijde DV, Mason D Jr, Landewé R, Vollenhoven RV, Combe B, et al. Certolizumab pegol plus methotrexate is significantly more effective than placebo plus methotrexate in active rheumatoid arthritis: findings of a fifty-two-week, phase III, multicenter, randomized, double-blind, placebo-controlled, parallel-group study. Arthritis Rheum 2008; 58: 3319-29. http://dx. doi. org/10. 1002/art. 23964.
235. Smolen J, Landewé RB, Mease P, Brzezicki J, Mason D, Luijtens K, et al. Efficacy and safety of certolizumab pegol plus methotrexate in active rheumatoid arthritis: the RAPID 2 study. A randomised controlled trial. Ann Rheum Dis 2009; 68: 797-804. http://dx. doi. org/10. 1136/ard. 2008. 101659.
236. Kremer J, Ritchlin C, Mendelsohn A, Baker D, Kim L, Xu Z, et al. Golimumab, a new human anti-tumor necrosis factor alpha antibody, administered intravenously in patients with active rheumatoid arthritis: forty-eight-week efficacy and safety results of a phase III randomized, double-blind, placebo-controlled study. Arthritis Rheum 2010; 62: 917-28. http://dx. doi. org/10. 1002/art. 27348.
237. O'Dell JR, Mikuls TR, Taylor TH, Ahluwalia V, Brophy M, Warren SR, et al. Therapies for active rheumatoid arthritis after methotrexate failure. N Engl J Med 2013; 369: 307-18. http://dx. doi. org/10. 1056/NEJMoa1303006.
238. van der Heijde D, Klareskog L, Rodriguez-Valverde V, Codreanu C, Bolosiu H, Melo-Gomes J, et al. Comparison of etanercept and methotrexate, alone and combined, in the treatment of rheumatoid arthritis: two-year clinical and radiographic results from the TEMPO study, a double-blind, randomized trial. Arthritis Rheum 2006; 54: 1063-74. http://dx. doi. org/10. 1002/art. 21655.
239. Keystone EC, Combe B, Smolen J, Strand V, Goel N, van Vollenhoven R, et al. Sustained efficacy of certolizumab pegol added to methotrexate in the treatment of rheumatoid arthritis: 2-year results from the RAPID 1 trial. Rheumatology 2012; 51: 1628-38. http://dx. doi. org/10. 1093/rheumatology/kes082.
240. Marcus SM. Assessing non-consent bias with parallel randomized and nonrandomized clinical trials. J Clin Epidemiol 1997; 50: 823-8. http://dx. doi. org/10. 1016/S0895-4356(97)00068-1.
241. Berger VW, Vali B. Intent-to-randomize corrections for missing data resulting from run-in selection bias in clinical trials for chronic conditions. J Biopharm Stat 2011; 21: 263-70. http://dx. doi. org/10. 1080/10543406. 2011. 550107.
242. Choy EH, Kingsley GH, Khoshaba B, Pipitone N, Scott DL. Intramuscular Methylprednisolone study group. A two year randomised controlled trial of intramuscular depot steroids in patients with established rheumatoid arthritis who have shown an incomplete response to disease modifying antirheumatic drugs. Ann Rheum Dis 2005; 64: 1288-93. http://dx. doi. org/10. 1136/ard. 2004. 030908.
243. Aletaha D, Smolen J, Ward MM. Measuring function in rheumatoid arthritis: identifying reversible and irreversible components. Arthritis Rheum 2006; 54: 2784-92. http://dx. doi. org/10. 1002/art. 22052.
244. Aletaha D, Strand V, Smolen JS, Ward MM. Treatment-related improvement in physical function varies with duration of rheumatoid arthritis: a pooled analysis of clinical trial results. Ann Rheum Dis 2008; 67: 238-43. http://dx. doi. org/10. 1136/ard. 2007. 071415.
245. Farewell VT, Su L. A multistate model for events defined by prolonged observation. Biostatistics 2011; 12: 102-11. http://dx. doi. org/10. 1093/biostatistics/kxq041.
246. Tennant A, Hillman M, Fear J, Pickering A, Chamberlain MA. Are we making the most of the Stanford Health Assessment Questionnaire? Br J Rheumatol 1996; 35: 574-8. http://dx. doi. org/10. 1093/rheumatology/35. 6. 574.
247. Wolfe F. Which HAQ is best? A comparison of the HAQ, MHAQ and RA-HAQ, a difficult 8 item HAQ (DHAQ), and a rescored 20 item HAQ (HAQ20): analyses in 2, 491 rheumatoid arthritis patients following leflunomide initiation. J Rheumatol 2001; 28: 982-9.
248. Scott DL, Garrood T. Quality of life measures: use and abuse. Baillieres Best Pract Res Clin Rheumatol 2000; 14: 663-87. http://dx. doi. org/10. 1053/berh. 2000. 0106.
249. Pollard L, Choy EH, Scott DL. The consequences of rheumatoid arthritis: quality of life measures in the individual patient. Clin Exp Rheumatol 2005; 23(Suppl. 39): S43-52.
250. Pope JE, Khanna D, Norrie D, Ouimet JM. The minimally important difference for the Health Assessment Questionnaire in rheumatoid arthritis clinical practice is smaller than in randomized controlled trials. J Rheumatol 2009; 36: 254-9. http://dx. doi. org/10. 3899/jrheum. 080479.
251. Scott DL, Grindulis KA, Struthers GR, Coulton BL, Popert AJ, Bacon PA. Progression of radiological changes in rheumatoid arthritis. Ann Rheum Dis 1984; 43: 8-17. http://dx. doi. org/10. 1136/ard. 43. 1. 8.
252. Scott DL, Greenwood A, Bryans R, Huskisson EC. Progressive joint damage during penicillamine therapy for rheumatoid arthritis. Rheumatol Int 1988; 8: 135-9. http://dx. doi. org/10. 1007/BF00272436.
253. Scott DL, Greenwood A, Davies J, Maddison PJ, Maddison MC, Hall ND. Radiological progression in rheumatoid arthritis: do D-penicillamine and hydroxychloroquine have different effects? Br J Rheumatol 1990; 29: 126-7. http://dx. doi. org/10. 1093/rheumatology/29. 2. 126.
254. Scott DL, Hanly JG, Moriarty M, Bresnihan B. The effect of lymphoid irradiation on the progression of joint damage in intractable rheumatoid arthritis. Arthritis Rheum 1988; 31: 147-8. http://dx. doi. org/10. 1002/art. 1780310124.
255. Soden M, Hassan J, Scott DL, Hanly JG, Moriarty M, Whelan A, et al. Lymphoid irradiation in intractable rheumatoid arthritis. Long-term follow-up of patients treated with 750 rads or 2000 rads. Arthritis Rheum 1989; 32: 523-30. http://dx. doi. org/10. 1002/anr. 1780320503.
256. Grindulis KA, Scott DL, Struthers GR. The assessment of radiological changes in the hands and wrists in rheumatoid arthritis. Rheumatol Int 1983; 3: 39-42. http://dx. doi. org/10. 1007/BF00541231.
257. Scott DL, Coulton BL, Bacon PA, Popert AJ. Methods of X-ray assessment in rheumatoid arthritis: a re-evaluation. Br J Rheumatol 1985; 24: 31-9. http://dx. doi. org/10. 1093/rheumatology/24. 1. 31.
258. Edmonds J, Saudan A, Lassere M, Scott D. Introduction to reading radiographs by the Scott modification of the Larsen method. J Rheumatol 1999; 26: 740-2.
259. Lassere M, Houssein D, Scott D, Edmonds J. Reference curves of radiographic damage in patients with rheumatoid arthritis: application of quantile regression and fractional polynomials. J Rheumatol 1997; 24: 1288-94.
260. Scott DL, Laasonen L, Priolo F, Houssien DA, Bacarini L, Cerase A, et al. The radiological assessment of rheumatoid arthritis. Clin Exp Rheumatol 1997; 15(Suppl. 17): S53-61.
261. Symmons D, Tricker K, Roberts C, Davies L, Dawes P, Scott DL. The British Rheumatoid Outcome Study Group (BROSG) randomised controlled trial to compare the effectiveness and cost-effectiveness of aggressive versus symptomatic therapy in established rheumatoid arthritis. Health Technol Assess 2005; 9(34).
262. van Riel PLCM, Scott DL. EULAR Handbook of Clinical Assessment in Rheumatoid Arthritis. Alphen Aan Den Rijn, the Netherlands: Van Zuiden Communications; 2000.
263. Scott DL, Antoni C, Choy EH, Van Riel PC. Joint counts in routine practice. Rheumatology 2003; 42: 919-23. http://dx. doi. org/10. 1093/rheumatology/keg235.
264. Scott DL, Choy EH, Greeves A, Isenberg D, Kassinor D, Rankin E, et al. Standardising joint assessment in rheumatoid arthritis. Clin Rheumatol 1996; 15: 579-82. http://dx. doi. org/10. 1007/BF02238547.
265. Stamp LK, Harrison A, Frampton C, Corkill MM. Does a joint count calibration exercise make a difference? Implications for clinical trials and training. J Rheumatol 2012; 39: 877-8. http://dx. doi. org/10. 3899/jrheum. 111224.
266. Hyrich KL, Watson KD, Lunt M, Symmons DP. Changes in disease characteristics and response rates among patients in the United Kingdom starting anti-tumor necrosis factor therapy for rheumatoid arthritis between 2001 and 2008. Rheumatology 2011; 50: 117-23. http://dx. doi. org/10. 1093/rheumatology/keq209.
267. Greenberg JD, Reed G, Decktor D, Harrold L, Furst D, Gibofsky A, et al. A comparative effectiveness study of adalimumab, etanercept and infliximab in biologically naive and switched rheumatoid arthritis patients: results from the US CORRONA registry. Ann Rheum Dis 2012; 71: 1134-42. http://dx. doi. org/10. 1136/annrheumdis-2011-150573.
268. Hetland ML, Christensen IJ, Tarp U, Dreyer L, Hansen A, Hansen IT, et al. Direct comparison of treatment responses, remission rates, and drug adherence in patients with rheumatoid arthritis treated with adalimumab, etanercept, or infliximab: results from eight years of surveillance of clinical practice in the nationwide Danish DANBIO registry. Arthritis Rheum 2010; 62: 22-32. http://dx. doi. org/10. 1002/art. 27227.
269. de Punder YM, Fransen J, Kievit W, Houtman PM, Visser H, van de Laar MA, et al. The prevalence of clinical remission in RA patients treated with anti-TNF: results from the Dutch Rheumatoid Arthritis Monitoring (DREAM) registry. Rheumatology 2012; 51: 1610-17. http://dx. doi. org/10. 1093/rheumatology/kes078.
270. Mancarella L, Bobbio-Pallavicini F, Ceccarelli F, Falappone PC, Ferrante A, Malesci D, et al. Good clinical response, remission, and predictors of remission in rheumatoid arthritis patients treated with tumor necrosis factor-alpha blockers: the GISEA study. J Rheumatol 2007; 34: 1670-3.
271. Listing J, Strangfeld A, Rau R, Kekow J, Gromnica-Ihle E, Klopsch T, et al. Clinical and functional remission: even though biologics are superior to conventional DMARDs overall success rates remain low-results from RABBIT, the German biologics register. Arthritis Res Ther 2006; 8: R66. http://dx. doi. org/10. 1186/ar1933.
272. Barton P, Bryan S, Robinson S. Modelling in the economic evaluation of health care: selecting the appropriate approach. J Health Serv Res Policy 2004; 9: 110-18. http://dx. doi. org/10. 1258/135581904322987535.
273. Bathon JM, McMahon DJ. Making rational treatment decisions in rheumatoid arthritis when methotrexate fails. N Engl J Med 2013; 369: 384-5. http://dx. doi. org/10. 1056/NEJMe1306381.
274. Fautrel B. Economic benefits of optimizing anchor therapy for rheumatoid arthritis. Rheumatology 2012; 51(Suppl. 4): iv21-6. http://dx. doi. org/10. 1093/rheumatology/kes088.
275. Kobelt G, Jönsson L, Lindgren P, Young A, Eberhardt K. Modeling the progression of rheumatoid arthritis: a two-country model to estimate costs and consequences of rheumatoid arthritis. Arthritis Rheum 2002; 46: 2310-19. http://dx. doi. org/10. 1002/art. 10471.
276. Korthals-de Bos I, Van Tulder M, Boers M, Verhoeven AC, Adèr HJ, Bibo J, et al. Indirect and total costs of early rheumatoid arthritis: a randomized comparison of combined step-down prednisolone, methotrexate, and sulfasalazine with sulfasalazine alone. J Rheumatol 2004; 31: 1709-16.
277. Verhoeven AC, Bibo JC, Boers M, Engel GL, van der Linden S. Cost-effectiveness and cost-utility of combination therapy in early rheumatoid arthritis: randomized comparison of combined step-down prednisolone, methotrexate and sulphasalazine with sulphasalazine alone. Br J Rheumatol 1998; 37: 1102-9. http://dx. doi. org/10. 1093/rheumatology/37. 10. 1102.
278. Bakker MF, Jacobs JW, Welsing PM, Verstappen SM, Tekstra J, Ton E, et al. Low-dose prednisone inclusion in a methotrexate-based, tight control strategy for early rheumatoid arthritis: a randomized trial. Ann Intern Med 2012; 156: 329-39. http://dx. doi. org/10. 7326/0003-4819-156-5-201203060-00004.
279. Choi HK, Seeger JD, Kuntz KM. A cost-effectiveness analysis of treatment options for patients with methotrexate-resistant rheumatoid arthritis. Arthritis Rheum 2000; 43: 2316-27. http://dx. doi. org/10. 1002/1529-0131(200010)43: 10<2316:: AID-ANR20>3. 0. CO; 2-6.
280. Tosh JC, Wailoo AJ, Scott DL, Deighton CM. Cost-effectiveness of combination nonbiologic disease-modifying antirheumatic drug strategies in patients with early rheumatoid arthritis. J Rheumatol 2011; 38: 1593-600. http://dx. doi. org/10. 3899/jrheum. 101327.
281. Osiri M, Shea B, Robinson V, Suarez-Almazor M, Strand V, Tugwell P, et al. Leflunomide for treating rheumatoid arthritis. Cochrane Database Syst Rev 2003; 1: CD002047.
282. Bingham SJ, Buch MH, Tennant A, Emery P. The impact of escalating conventional therapy in rheumatoid arthritis patients referred for anti-tumour necrosis factor-alpha therapy. Rheumatology 2004; 43: 364-8. http://dx. doi. org/10. 1093/rheumatology/keh057.
283. Strand V, Sokolove J. Randomized controlled trial design in rheumatoid arthritis: the past decade. Arthritis Res Ther 2009; 11: 205. http://dx. doi. org/10. 1186/ar2555.
284. Concato J, Shah N, Horwitz RI. Randomized, controlled trials, observational studies, and the hierarchy of research designs. N Engl J Med 2000; 342: 1887-92. http://dx. doi. org/10. 1056/NEJM200006223422507.
285. Kievit W, Fransen J, Oerlemans AJ, Kuper HH, van der Laar MA, de Rooij DJ, et al. The efficacy of anti-TNF in rheumatoid arthritis, a comparison between randomised controlled trials and clinical practice. Ann Rheum Dis 2007; 66: 1473-8. http://dx. doi. org/10. 1136/ard. 2007. 072447.
286. Fries JF, Krishnan E. Equipoise, design bias, and randomized controlled trials: the elusive ethics of new drug development. Arthritis Res Ther 2004; 6: 250-5. http://dx. doi. org/10. 1186/ar1170.
287. Lilford RJ. Ethics of clinical trials from a Bayesian and decision analytic perspective: whose equipoise is it anyway? BMJ 2003; 326: 980-1. http://dx. doi. org/10. 1136/bmj. 326. 7396. 980.
288. Djulbegovic B, Lacevic M, Cantor A, Fields KK, Bennett CL, Adams JR, et al. The uncertainty principle and industry-sponsored research. Lancet 2000; 356: 635-8. http://dx. doi. org/10. 1016/S0140-6736(00)02605-2.
289. Felson DT, Glantz L. A surplus of positive trials: weighing biases and reconsidering equipoise. Arthritis Res Ther 2004; 6: 117-19. http://dx. doi. org/10. 1186/ar1189.
290. Ashcroft RE. Ethics of randomised controlled trials-not yet time to give up on equipoise. Arthritis Res Ther 2004; 6: 237-9. http://dx. doi. org/10. 1186/ar1442.
291. Lavori PW, Rush AJ, Wisniewski SR, Alpert J, Fava M, Kupfer DJ, et al. Strengthening clinical effectiveness trials: equipoise-stratified randomization. Biol Psychiatry 2001; 50: 792-801. http://dx. doi. org/10. 1016/S0006-3223(01)01223-9.
292. Lempp H, Scott DL, Kingsley GH. Patients' views on the quality of health care for rheumatoid arthritis. Rheumatology 2006; 45: 1522-8. http://dx. doi. org/10. 1093/rheumatology/kel132.
293. Lempp H, Scott DL, Kingsley GH. The personal impact of rheumatoid arthritis on patients' identity. Chronic Illn 2006; 2: 109-20. http://dx. doi. org/10. 1177/17423953060020020601.
294. Lempp H, Hofmann D, Hatch SL, Scott DL. Patients' views about treatment with combination therapy for rheumatoid arthritis: a comparative qualitative study. BMC Musculoskelet Disord 2012; 13: 200. http://dx. doi. org/10. 1186/1471-2474-13-200.
295. Isaacs JD, Ferraccioli G. The need for personalised medicine for rheumatoid arthritis. Ann Rheum Dis 2011; 70: 4-7. http://dx. doi. org/10. 1136/ard. 2010. 135376.
296. Miossec P, Verweij CL, Klareskog L, Pitzalis C, Barton A, Lekkerkerker F, et al. Biomarkers and personalised medicine in rheumatoid arthritis: a proposal for interactions between academia, industry and regulatory bodies. Ann Rheum Dis 2011; 70: 1713-18. http://dx. doi. org/10. 1136/ard. 2011. 154252.
297. Rahman MU, Buchanan J, Doyle MK, Hsia EC, Gathany T, Parasuraman S, et al. Changes in patient characteristics in anti-tumor necrosis factor clinical trials for rheumatoid arthritis: results of an analysis of the literature over the past 16 years. Ann Rheum Dis 2011; 70: 1631-40. http://dx. doi. org/10. 1136/ard. 2010. 146043.
298. Sokka T, Pincus T. Eligibility of patients in routine care for major clinical trials of anti-tumor necrosis factor alpha agents in rheumatoid arthritis. Arthritis Rheum 2003; 48: 313-18. http://dx. doi. org/10. 1002/art. 10817.
299. Sokka T, Pincus T. Most patients receiving routine care for rheumatoid arthritis in 2001 did not meet inclusion criteria for most recent clinical trials or American College of Rheumatology criteria for remission. J Rheumatol 2003; 30: 1138-46.
300. Zink A, Strangfeld A, Schneider M, Herzer P, Hierse F, Stoyanova-Scholz M, et al. Effectiveness of tumor necrosis factor inhibitors in rheumatoid arthritis in an observational cohort study: comparison of patients according to their eligibility for major randomized clinical trials. Arthritis Rheum 2006; 54: 3399-407. http://dx. doi. org/10. 1002/art. 22193.
301. Tunis SR, Stryer DB, Clancy CM. Practical clinical trials: increasing the value of clinical research for decision making in clinical and health policy. JAMA 2003; 290: 624-32. http://dx. doi. org/10. 1001/jama. 290. 12. 1624.
302. Garattini S, Bertele' V. How can we regulate medicines better? BMJ 2007; 335: 803-5. http://dx. doi. org/10. 1136/bmj. 39281. 615706. 94.
303. Stafford RS, Wagner TH, Lavori PW. New, but not improved? Incorporating comparative-effectiveness information into FDA labeling. N Engl JMed 2009; 361: 1230-3. http://dx. doi. org/10. 1056/NEJMp0906490.